Todd Sone

Todd is a Partner at aMoon and has over 20 years of healthcare investment experience. Todd serves on the boards of Ayala Pharmaceuticals (AYLA), Biolojic Design, Theranica, and Smart Medical Systems. Prior to joining aMoon, he was a Managing Director at Signet Healthcare Partners and served on the boards of Arbor Pharmaceuticals (sold to KKR), Apicore (sold to Medicure) and co-led the investment in Claris Lifesciences (sold to Baxter). Prior to Signet, Todd was an Investment Director at Joddes, a family office with interests in a number of leading life science companies, including Pharmascience, Paladin Labs and Medicom. He was previously a large-cap pharmaceutical analyst at Morgan Stanley. He started his career in strategy consulting at Mercer Management Consulting. Todd received a B.Com (High Distinction) from the University of Toronto and an MBA from The Wharton School with concentrations in healthcare management and finance.